# EDGAR Filing Document

**Accession Number:** 0001555280
**File Stem:** 0001628280-26-043958
**Filing Date:** 2026-6
**Character Count:** 9578
**Document Hash:** f959b20ebb4c63d61c82b9c7f475605c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-043958.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001628280-26-043958

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260615

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nayak Abhay U
- **CENTRAL INDEX KEY:** 0001797754

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35797
- **FILM NUMBER:** 261099181

**MAIL ADDRESS:**
- **STREET 1:** C/O ZOETIS INC.
- **STREET 2:** 10 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zoetis Inc.
- **CENTRAL INDEX KEY:** 0001555280
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 460696167
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** 973-822-7000

**MAIL ADDRESS:**
- **STREET 1:** 10 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

## Ex-24

![](anayakpoa001.jpg)

------

![](anayakpoa002.jpg)

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nayak Abhay U<br><sub>(Last) (First) (Middle)</sub><br>C/O ZOETIS INC.<br>10 SYLVAN WAY<br><sub>(Street)</sub><br>PARSIPPANY, NJ 07054<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Zoetis Inc. [ ZTS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-06-15 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Executive Vice President_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| No securities beneficially held | 0 | D<sup>(1)</sup> |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit<sup>(2)</sup> | <sup>(3)</sup> | <sup>(4)</sup> | Common Stock | 1122.8284 | <sup>(5)</sup> | D |  |
| Restricted Stock Unit<sup>(2)</sup> | <sup>(6)</sup> | <sup>(4)</sup> | Common Stock | 1902.1798 | <sup>(5)</sup> | D |  |
| Restricted Stock Unit<sup>(2)</sup> | <sup>(7)</sup> | <sup>(4)</sup> | Common Stock | 625.6906 | <sup>(5)</sup> | D |  |
| Restricted Stock Unit<sup>(2)</sup> | <sup>(8)</sup> | <sup>(4)</sup> | Common Stock | 253.0883 | <sup>(5)</sup> | D |  |
| Stock Option<sup>(9)</sup> | <sup>(10)</sup> | <sup>(11)</sup> | Common Stock | 4423 | $129.13 | D |  |
| Stock Option<sup>(9)</sup> | <sup>(12)</sup> | <sup>(11)</sup> | Common Stock | 3590 | $156.64 | D |  |
| Stock Option<sup>(9)</sup> | <sup>(13)</sup> | <sup>(11)</sup> | Common Stock | 2830 | $196.14 | D |  |
| Stock Option<sup>(9)</sup> | <sup>(14)</sup> | <sup>(11)</sup> | Common Stock | 3314 | $162.07 | D |  |
| Stock Option<sup>(15)</sup> | <sup>(16)</sup> | <sup>(11)</sup> | Common Stock | 8106 | <sup>(17)</sup> | D |  |
| Phantom Stock Unit<sup>(18)</sup> | <sup>(18)</sup> | <sup>(18)</sup> | Common Stock | 1508.7729 | <sup>(19)</sup> | D |  |

---

### Footnotes:

(1) The  reporting person was a Section 16 officer of Zoetis Inc., in his capacity as Executive Vice President, from January 1, 2020 to October 31, 2022, and as a result filed a Form 3 on January 8, 2020, and filed his last Form 4 on October 11, 2022.  The securities reported as beneficially owned in this Form 3 reflect unreported transactions that occurred between October 11, 2022 and June 15, 2026, the date on which the reporting person again became a Section 16 officer for Zoetis Inc.

(2) Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs").

(3) One-third of each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, February 18, 2026; subject to the reportingperson's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

(4) Not applicable.

(5) Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.

(6) One-third of each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, January 30, 2026; subject to the reportingperson's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

(7) One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, February 19, 2025; subject to the reportingperson's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

(8) One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant, February 6, 2024; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

(9) Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.

(10) One-third of each option will vest on the first, second and third anniversaries of the date of grant, February 18, 2026.

(11) Each option expires on the tenth anniversary of the date of grant.

(12) One-third of each option vests on the first, second and third anniversaries of the date of grant, February 19, 2025.

(13) One-third of each option vests on the first, second and third anniversaries of the date of grant, February 6, 2024.

(14) One-third of each option vested on the first, second and third anniversaries of the date of grant, February 8, 2023.

(15) Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan.

(16) Each option vested on the third anniversary of the date of grant.

(17) 1,147 options granted February 12, 2019 at an exercise price of $87.51 per option; 1,658 options granted February 11, 2020 at an exercise price of $144.03 per option; 2,478 options granted February 10, 2021 at an exercise price of $160.62 per option; and 2,823 options granted February 8, 2022 at an exercise price of $201.30 per option.

(18) These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.

(19) Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit). Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.

**Signature:** /s/ Brenda Santuccio, as Attorney-in-Fact  
**Date:** 2026-06-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**